Published in MBio on August 26, 2014
Bacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore Persistence. PLoS Pathog (2016) 1.40
Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine. J Infect Dis (2015) 1.00
Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine. Clin Vaccine Immunol (2015) 0.92
Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol (2014) 0.91
A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens. PLoS One (2015) 0.84
Hijacking Complement Regulatory Proteins for Bacterial Immune Evasion. Front Microbiol (2016) 0.80
Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine. Vaccine (2015) 0.80
Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein. MBio (2015) 0.80
Outer membrane vesicles as platform vaccine technology. Biotechnol J (2015) 0.80
A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice. Vaccine (2015) 0.79
A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine (2015) 0.79
Susceptibility to invasive meningococcal disease: polymorphism of complement system genes and Neisseria meningitidis factor H binding protein. PLoS One (2015) 0.79
Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine Against Genetically Diverse Serogroup B Meningococci. Clin Vaccine Immunol (2016) 0.79
A Newly-Identified Polymorphism in Rhesus Macaque Complement Factor H Modulates Binding Affinity for Meningococcal FHbp. PLoS One (2015) 0.78
Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity. Clin Vaccine Immunol (2016) 0.78
Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Infect Immun (2015) 0.78
Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight (2016) 0.77
A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes. Proc Natl Acad Sci U S A (2015) 0.76
The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection. PLoS One (2016) 0.75
Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H. Infect Immun (2016) 0.75
Licensed meningococcal serogroup B vaccine-induced immunity against invasive disease does not reflect protection against nasal colonization in a humanized mouse model. J Infect Dis (2017) 0.75
The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine (2017) 0.75
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 5.63
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Global epidemiology of meningococcal disease. Vaccine (2009) 4.26
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun (2004) 3.29
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature (2009) 2.81
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun (2008) 2.29
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis (1986) 2.16
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol (2007) 1.71
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun (2008) 1.61
Review of meningococcal group B vaccines. Clin Infect Dis (2010) 1.58
Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun (2011) 1.29
Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol Med (2001) 1.23
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines (2013) 1.13
Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun (2001) 1.09
Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine (2013) 1.05
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev (2013) 1.05
Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun (2009) 1.04
Adjuvant effect of gamma-inulin is mediated by C3 fragments deposited on antigen-presenting cells. J Leukoc Biol (2001) 1.02
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis (2013) 1.01
Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules (2012) 0.99
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J Innate Immun (2013) 0.96
Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun (2013) 0.95
Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels. J Biol Chem (2010) 0.94
Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One (2012) 0.89
Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol (2012) 0.88
Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther (2012) 0.86
Involvement of Neisseria meningitidis lipoprotein GNA2091 in the assembly of a subset of outer membrane proteins. J Biol Chem (2014) 0.83
Identification of a Haemophilus influenzae factor H-Binding lipoprotein involved in serum resistance. J Immunol (2014) 0.82
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol (2014) 0.91
Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity. Infect Immun (2015) 0.86